Progress on relation between human leukocyte antigen gene and oxcarbazepine induced cutaneous adverse drug reactions
10.3760/cma.j.issn.1008-5734.2018.02.010
- VernacularTitle:奥卡西平皮肤不良反应与人类白细胞抗原基因相关性的研究进展
- Author:
Qingqing FAN
1
;
Han XIE
;
Tianhua YAN
;
Weihong GE
Author Information
1. 210008 南京大学医学院附属鼓楼医院药学部;210009南京,中国药科大学基础医学与临床药学学院
- Publication Type:Journal Article
- Keywords:
Drug toxicity;
Stevens-Johnson syndrome;
Epidermal necrolysis;
toxic;
Human leukocyte antigens
- From:
Adverse Drug Reactions Journal
2018;20(2):135-139
- CountryChina
- Language:Chinese
-
Abstract:
Oxcarbazepine(OXC)is a new antiepileptic drug developed through structural variation of carbamazepine and widely used for the patient who cannot tolerate carbamazepine. Although OXC has a lower risk of cutaneous adverse drug reactions(cADRs)than carbamazepine,it has been reported that OXC-induced cutaneous adverse drug reactions(OXC-cADRs)are prevalent and may lead to drug discontinua-tion. HLA-B﹡15:02 is associated with oxcarbazepine-induced SJS/TEN,but not maculopapule,which is similar to carbamazepine. In addition,HLA-A﹡13:02,HLA-B﹡38:02 and HLA-B﹡40:02 are HLAⅠtype genes which is related to oxcarbazepine-induced maculopapule(OXC-MPE),and HLA-DRB1﹡04:03 was first HLA class Ⅱ gene found associated with OXC-MPE. The risk factor of OXC-cADRs is still not completely clear. Age,gender,weight and total dose of medication were not correlated with OXC-MPE. Allergy induced by antiepileptic drugs and non-antiepileptic drug induced allergy may be risk factors of OXC-cADRs. Attention should be paid to cross-allergic reactions before using oxcarbazepine for patients with a history of carbamazepine-induced allergy. Genetic test is not currently recommended in patients with maculopapule. Aromatic antiepileptic drugs should be avoided in patients with positive expression of HLA-B﹡15:02 gene.
